The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer.
Didier Trono, Evaristo Jose Planet Letschert, Nikolaos Lykoskoufis
Cathrin Brisken, Hazel Margaret Quinn, Patrik Aouad